Entrada Therapeutics
TRDA
103 hedge funds and large institutions have $560M invested in Entrada Therapeutics in 2024 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 43 increasing their positions, 24 reducing their positions, and 14 closing their positions.
596% more call options, than puts
Call options by funds: $717K | Put options by funds: $103K
79% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 24
43% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 14
16% more capital invested
Capital invested by funds: $481M → $560M (+$78.8M)
6% more funds holding
Funds holding: 97 → 103 (+6)
5.61% more ownership
Funds ownership: 80.91% → 86.52% (+5.6%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$6.68M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.37M |
| 3 |
Goldman Sachs
New York
|
+$3.64M |
| 4 |
BlackRock
New York
|
+$2.75M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$2.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.22M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.66M |
| 3 |
Millennium Management
New York
|
-$1.78M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$1.6M |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$960K |
TRDA Hedge Fund Activity: Q4 2024 in Review
103 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Entrada Therapeutics (TRDA) for Q4 2024, worth a combined $560M — up 16% from $481M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new TRDA positions and 14 closed out — a net gain of 6 holders — while 43 added to existing stakes and 24 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $6.68M. The largest seller was Fidelity Investments, cutting an estimated $6.22M.
- 103 institutional investors held Entrada Therapeutics (TRDA) as of Q4 2024, up from 97 in Q3 2024.
- Funds reported $560M of Entrada Therapeutics stock for Q4 2024, up 16% quarter-over-quarter.
- 20 funds opened new Entrada Therapeutics positions in Q4 2024 and 14 closed out, a net change of +6 holders.
- The largest Entrada Therapeutics buyer in Q4 2024 was Janus Henderson Group, an estimated $6.68M added.
- The largest Entrada Therapeutics seller in Q4 2024 was Fidelity Investments, an estimated $6.22M sold.
Based on aggregated 13F filings for Q4 2024.